Document Detail

Intravenous immunoglobulin in the management of hemolytic disease of the newborn.
MedLine Citation:
PMID:  16383181     Owner:  NLM     Status:  MEDLINE    
Jaundice caused by hemolysis continues to challenge practitioners caring for infants in the NICU. Bilirubin levels can rise quickly in the first days of life, and interventions must be prompt to prevent side effects related to hyperbilirubinemia. Conventional treatments such as hydration and phototherapy are common, but new studies suggest that use of intravenous immunoglobin (IVIG) as an additional treatment may prevent the need for exchange transfusion in some babies. This article presents a case study of an infant with blood-type incompatibility treated successfully with multiple doses of IVIG, discusses the pathophysiology and clinical presentation of hemolytic jaundice, and reviews current management strategies for this disease.
Cynthia A Mundy
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Neonatal network : NN     Volume:  24     ISSN:  0730-0832     ISO Abbreviation:  Neonatal Netw     Publication Date:    2005 Nov-Dec
Date Detail:
Created Date:  2005-12-30     Completed Date:  2006-02-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8503921     Medline TA:  Neonatal Netw     Country:  United States    
Other Details:
Languages:  eng     Pagination:  17-24     Citation Subset:  N    
School of Nursing, Medical College of Georgia, Augusta 30912, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
ABO Blood-Group System
Bilirubin / blood
Blood Group Incompatibility / complications
Clinical Protocols
Drug Monitoring
Erythroblastosis, Fetal / blood,  etiology,  therapy*
Exchange Transfusion, Whole Blood
Immunoglobulins, Intravenous / therapeutic use*
Immunologic Factors / therapeutic use*
Infant, Newborn
Infusions, Intravenous
Jaundice, Neonatal / etiology
Metalloporphyrins / therapeutic use
Neonatal Nursing
Nurse's Role
Rh Isoimmunization / complications
Reg. No./Substance:
0/ABO Blood-Group System; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors; 0/Metalloporphyrins; 635-65-4/Bilirubin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Putting babies "back to sleep": can we do better?
Next Document:  A concept analysis of family-centered care in the NICU.